Cox-2 inhibitors and cardiovascular risk: the data are inconclusive, and these drugs are needed.
Lipani
J
J
Histatek Inc, Fountain Hills, AZ, USA.
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D000075202:Contraindications; D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006801:Humans; D007527:Isoenzymes / Q000037:antagonists & inhibitors*; D008565:Membrane Proteins; D009203:Myocardial Infarction / Q000139:chemically induced* / Q000453:epidemiology; D011451:Prostaglandin-Endoperoxide Synthases; D016032:Randomized Controlled Trials as Topic; D012107:Research Design; D012306:Risk
D000894:Anti-Inflammatory Agents, Non-Steroidal; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D007527:Isoenzymes; D008565:Membrane Proteins; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases